Table 1.
List of PD-L1/PD-1 blockade approved therapies in different types of cancers.
| Cancer | FDA Approved Agents | Clinical Trial (s) |
|---|---|---|
| Merkel cell carcinoma (Skin cancer) | Avelumab (2017) | JAVELIN phase 2 |
| Pembrolizumab (2018) | KEYNOTE-017 phase 2 | |
| Melanoma (Skin Cancer) |
Pembrolizumab (2014) | KEYNOTE-001 phase 1 |
| Nivolumab (2014) | CheckMate-037 | |
| Nivolumab + ipilimumab (2015) | CheckMate-069 | |
| Pembrolizumab (2015) | KEYNOTE-006 phase 3 | |
| Nivolumab + ipilimumab (2016) | CheckMate-067 phase 3 | |
| Nivolumab (2017) | CheckMate-238 phase 3 | |
| Primary mediastinal large B-cell lymphoma (Blood cancer) |
Pembrolizumab (2018) | KEYNOTE-170 phase 2 |
| Classical Hodgkin lymphoma (Blood Cancer) |
Nivolumab (2016) | CheckMate-039 phase 1 and Checkmate-205 phase 2 |
| Pembrolizumab (2017) | KEYNOTE-087 phase 2 | |
| Small cell lung cancer | Nivolumab (2018) | CheckMate-032 phase ½ |
| Non-small cell lung cancer | Nivolumab (2015) | CheckMate-017 phase 3 |
| Pembrolizumab (2015) | CheckMate-057 phase 3 | |
| Atezolizumab (2016) | POPLAR phase 2 and OAK phase 3 | |
| Pembrolizumab (2016) | KEYNOTE-024 phase 3 | |
| Pembrolizumab + Caroplatin + Pemetrexed (2017) | KEYNOTE-024 phase 3 | |
| Durvalumab (2018) | KEYNOTE-021 phase 2 | |
| Pembrolizumab + Pemetrexed + Platinum (2018) | PACIFIC phase 3 KEYNOTE-189 phase 3 |
|
| Microsatellite instability-high and DNA mismatch repair deficiency unresectable solid tumors (Gastrointestinal Cancer) | Pembrolizumab (2017) | KEYNOTE-164 phase 2 |
| Nivolumab (2017) | CheckMate-142 phase 2 | |
| Nivolumab + ipilimumab (2018) | CheckMate-142 phase 2 | |
| Hepatocellular carcinoma | Nivolumab (2017) | CheckMate-040 phase ½ |
| Pembrolizumab (2018) | KEYNOTE-224 phase 2 | |
| Gastric cancer | Pembrolizumab (2017) | KEYNOTE-059 phase 2 |
| Renal cell cancer | Nivolumab (2015) | CheckMate-025 phase 3 |
| Nivolumab + ipilimumab (2018) | CheckMate-025 phase 3 | |
| Urothelial cancer (Renal Cancer) |
Atezolizumab (2016) | IMVigor 210 phase 2 |
| Nivolumab (2017) | CheckMate-275 phase 2 | |
| Atezolizumab (2017) | IMVigor 210 phase 2 | |
| Durvalumab (2017) | Study 1108 phase 2 | |
| Avelumab (2017) | JAVELIN solid tumor phase 1 | |
| Pembrolizumab (2017) | KEYNOTE-052 phase 2 KEYNOTE-045 phase 3 |
|
| Cervical cancer | Pembrolizumab (2018) | KEYNOTE-158 phase 2 |
| Head and Neck squamous cell carcinoma | Pembrolizumab (2016) | KEYNOTE-012 phase 1b |
| Nivolumab (2016) | CheckMate-141 phase 3 |